Shilpa Medicare gains on Europe drug approval for Parkinson's patch
12/12/2025 08:00
** Shares of Shilpa Medicare SHME.NS rise as much as 3.8% to 340 rupees; stock currently up 1.6% ** Pharma co receives initial authorisation for marketing Rotigotine transdermal patch, used for treatment of Restless Legs Syndrome and Parkinson's disease, in Europe ** Co says total addressable European market is estimated at about $222 million ** More than 435,780 shares change hands vs 30-day avg of 276,991 shares ** YTD, stock down 18.4% (Reporting by Mridula Kumar in Bengaluru) ((Mridula.Kumar@thomsonreuters.com;))
Recent news on Shilpa Medicare
See all newsBrief: Shilpa Medicare Q2 Consol Net Profit INR 791.8 Million
Brief: Shilpa Medicare Says USFDA Conducts Surveillance Inspection At Shilpa Medicare Unit
Brief: Shilpa Medicare Receives Final SEC Approval For Oeris Marketing Authorization
India's Shilpa Medicare gains on approval for OERIS
Brief: Shilpa Medicare Initiates Voluntary Recall Of 27,923 Pemetrexed Injection Vials In Us On July 29, 2026